NEW YORK (GenomeWeb News) – Dementia diagnostics firm Cytox today said that it raised £1.5 million ($2.5 million) in a second round of funding.

The financing was led by existing investor Spark Impact, manager of The North West Fund for Biomedical. Other existing investors, including Wren Capital, the Rainbow Seed Fund, and private investors also participated in the round, as did new investor Seneca Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.